clinical trial · NCT04603300
OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
Peanut AllergyINT301Placebo
brief summary
This is a phase 1, multi-center, randomized, double-blind, placebo-controlled study in adult participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive either an escalating dose of INT301 or placebo. The treatment group will be blinded to the investigator, participants, and the Intrommune study team.
started
May 15, 2021
primary completion
Jun 30, 2023
completion
Jun 30, 2023
last updated
Jul 28, 2023
official title
Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol